abstract |
The present invention relates to the administration of vascular targeting agents, especially tubulin binding agents, to treat ocular angiogenesis, ocular tumors, and symptoms such as diabetic retinopathy, prematurity retinopathy, retinoblastoma and macular degeneration. |